STOCK TITAN

Pittman boosts Nuo Therapeutics (AURX) position with 11.6% stake and secured, warrant-backed loan

Filing Impact
(Moderate)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13D/A

Rhea-AI Filing Summary

Nuo Therapeutics investor Scott M. Pittman reports beneficial ownership of 5,610,050 shares of common stock, or 11.6% of the company, based on 48,281,625 shares outstanding as of January 21, 2026. His holdings include 5,400,000 shares held directly, 30,050 shares issuable upon exercise of newly received warrants, and 180,000 shares underlying options.

The amendment also describes a secured loan arrangement where Pittman has loaned $200,000 to Nuo Therapeutics and committed to an additional $210,000 if requested. The notes bear interest at 10%, rising to 12% if a second closing occurs, and mature on December 31, 2028. Interest and certain prepayment fees are payable in stock warrants rather than cash, with multiple warrant series exercisable at $1.50 per share and expiring January 23, 2030, giving Pittman additional potential equity exposure through commitment, origination, capital coverage, prepayment, second-closing, and interest warrants.

Positive

  • None.

Negative

  • None.

Insights

Insider reports 11.6% stake and extends secured, warrant-heavy financing.

This amendment shows Scott M. Pittman holding 5,610,050 shares, or 11.6% of Nuo Therapeutics common stock, combining directly held shares, options, and immediately exercisable warrants. The ownership calculation is based on 48,281,625 shares outstanding as of January 21, 2026, as represented in the loan agreement.

The filing also details a $200,000 secured loan already funded, with a committed additional $210,000 possible at a second closing. The notes accrue interest at 10% initially, stepping to 12% if the second closing occurs, and mature on December 31, 2028. Repayment is interest-only until the end of 2026, then amortizes quarterly in cash, while interest and prepayment fees are settled in warrants rather than cash.

Multiple warrant series, all with a $1.50 exercise price and a January 23, 2030 expiration, enhance Pittman’s potential equity exposure. These include immediately exercisable warrants for 30,050 shares and additional warrants tied to second-closing, capital coverage, prepayment events, and accrued interest. Actual dilution and ownership impact will depend on future events such as equity financings, changes of control, prepayments, and warrant exercises as described in the agreement.






If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).






SCHEDULE 13D






SCHEDULE 13D


Pittman Scott M.
Signature:/s/ Scott M. Pittman
Name/Title:Scott M. Pittman
Date:01/26/2026

FAQ

What percentage of Nuo Therapeutics (AURX) does Scott M. Pittman beneficially own?

Scott M. Pittman beneficially owns 5,610,050 shares of Nuo Therapeutics common stock, representing 11.6% of the class. This figure includes 5,400,000 shares held directly, 30,050 shares issuable upon exercise of newly issued Initial Warrants, and 180,000 shares underlying stock options, based on 48,281,625 shares outstanding as of January 21, 2026.

How many Nuo Therapeutics (AURX) shares does Pittman hold directly versus through derivatives?

Pittman holds 5,400,000 Nuo Therapeutics shares directly. In addition, he has derivative exposure to 210,050 shares through equity-linked instruments: 30,050 shares issuable upon exercise of Initial Warrants and 180,000 shares issuable upon exercise of options, all counted in his 5,610,050-share beneficial ownership.

What are the key terms of Scott M. Pittman’s loan to Nuo Therapeutics (AURX)?

Pittman has loaned $200,000 to Nuo Therapeutics under a secured Loan and Security Agreement and committed to an additional $210,000 if requested. The Initial Note bears 10% annual interest, increasing to 12% if a second funding occurs on or after September 30, 2026, with both notes maturing on December 31, 2028. Interest is payable in Interest Warrants at maturity or earlier prepayment, and the notes are secured by a lien on all company assets, including intellectual property.

What warrant package did Nuo Therapeutics (AURX) grant to Pittman in connection with the loan?

At the initial closing on January 23, 2026, Pittman received several warrant series tied to his loan commitment and funding. These include: a Commitment Warrant for 2,050 shares, an Origination Initial Warrant for 1,333 shares, a Capital Initial Warrant for 26,667 shares, an Origination Second Warrant for 1,750 shares (vesting only if a second closing occurs), a Capital Second Warrant for 35,000 shares (also vesting upon a second closing), and a Prepayment Warrant for up to 7,516 shares vesting upon specified prepayments. All have a $1.50 exercise price and expire January 23, 2030.

How is interest on Pittman’s notes from Nuo Therapeutics (AURX) paid?

Interest on the notes is paid in the form of stock warrants rather than cash. Interest accrues quarterly and is payable at the December 31, 2028 maturity date, or earlier upon certain prepayments, through issuance of Interest Warrants. An Interest Warrant exercisable for up to 55,100 shares is issuable to Pittman at maturity or earlier prepayment events, using an exercise price of $1.50 per share.

What events can trigger mandatory prepayment of Pittman’s notes by Nuo Therapeutics (AURX)?

The notes must be prepaid in full if Nuo Therapeutics completes an equity financing of at least $5 million, undergoes certain defined changes in control, or defaults under the agreement. In such cases, the company must pay the then-outstanding principal and accrued interest, plus a prepayment fee of 2.75% of principal if the event occurs before December 31, 2026, 1.5% if between December 31, 2026 and December 31, 2027, and no fee if on or after December 31, 2027. The prepayment fee is settled in Prepayment Warrants.

Nuo Therapeutics

OTC:AURX

AURX Rankings

AURX Latest News

AURX Latest SEC Filings

AURX Stock Data

86.40M
20.06M
59.18%
2.2%
Biotechnology
Healthcare
Link
United States
Houston